Next Article in Journal
Muscle Involvement in Amyotrophic Lateral Sclerosis: Understanding the Pathogenesis and Advancing Therapeutics
Previous Article in Journal
Supplementing L-Citrulline Can Extend Lifespan in C. elegans and Attenuate the Development of Aging-Related Impairments of Glucose Tolerance and Intestinal Barrier in Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 11
10.3390/biom13111581
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety

by
Hung-Jin Huang
1,†,
Chu-Lin Chou
1,2,3,
Tin Tin Sandar
4,
Wen-Chih Liu
5,6,
Hsiu-Chien Yang
7,8,
Yen-Chung Lin
1,3,9,†,
Cai-Mei Zheng
1,3,10,* and
Hui-Wen Chiu
3,11,12,13,*
1
Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
2
Division of Nephrology, Department of Internal Medicine, Hsin Kuo Min Hospital, Taipei Medical University, Taoyuan City 320, Taiwan
3
TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei 110, Taiwan
4
Cancer Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford OX3 7LF, UK
5
Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan
6
Section of Nephrology, Department of Medicine, Antai Medical Care Corporation Antai Tian-Sheng Memorial Hospital, Pingtung 928, Taiwan
7
Division of Nephrology, Department of Internal Medicine, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung 813, Taiwan
8
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
9
Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan
10
Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan
11
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
12
Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan
13
Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomolecules 2023, 13(11), 1581; https://doi.org/10.3390/biom13111581
Submission received: 26 August 2023 / Revised: 22 October 2023 / Accepted: 24 October 2023 / Published: 26 October 2023
Browse Figures
Versions Notes

Abstract

:
Kidney diseases with kidney failure or damage, such as chronic kidney disease (CKD) and acute kidney injury (AKI), are common clinical problems worldwide and have rapidly increased in prevalence, affecting millions of people in recent decades. A series of novel diagnostic or predictive biomarkers have been discovered over the past decade, enhancing the investigation of renal dysfunction in preclinical studies and clinical risk assessment for humans. Since multiple causes lead to renal failure, animal studies have been extensively used to identify specific disease biomarkers for understanding the potential targets and nephropathy events in therapeutic insights into disease progression. Mice are the most commonly used model to investigate the mechanism of human nephropathy, and the current alternative methods, including in vitro and in silico models, can offer quicker, cheaper, and more effective methods to avoid or reduce the unethical procedures of animal usage. This review provides modern approaches, including animal and nonanimal assays, that can be applied to study chronic nonclinical safety. These specific situations could be utilized in nonclinical or clinical drug development to provide information on kidney disease.

1. Introduction

Kidney-related diseases, such as acute kidney injury (AKI), diabetic kidney disease (DKD), chronic kidney disease (CKD), and end-stage renal disease (ESRD), continue to remain a considerable problem in the clinic. For preclinical safety assessment, nonclinical biomarkers are used to determine how well the body responds through biochemical changes in both nonclinical species and humans to assess the safety and efficacy of novel compounds [1]. Traditionally, drug developers have used biochemical markers to detect renal injury. However, there is room for innovation in discovering novel markers of kidney disease in drug development. The research of uncovered new biomarkers has two main scientific styles: hypothesis-based and discovery-based investigations [2]. The candidate biomarkers identified by the hypothesis-based approach are based on the knowledge of disease processes with the product of ever-increasing mechanistic understanding [3]. For instance, detecting glycosylated hemoglobin with a sustained elevation of blood glucose levels can be a biomarker for diagnosing diabetes mellitus. The discovery-based method focuses on monitoring the changes in the abundance of molecular species associated with the disease of interest. An example of a discovery-based study is the search for the BRCA1 gene in breast and ovarian cancer, which was frequently lost in the region of chromosome 17q21 in breast cancer [4].
Traditionally, the diagnosis or prognosis of renal disease based on biomarkers is essential for developing and evaluating potential treatments. The prognostic biomarkers determine the relationship between the disease and clinical outcome in the absence of medication and therapy, while the predictive biomarkers measure whether a patient is most likely to benefit from a particular treatment [5]. Biomarkers can be used to measure quantitative parameters, such as genes [6], proteins [7], microRNAs [8], lipids [9], and metabolites in serum [10], to examine whether the kidney function of patients is healthy or abnormal on urinalysis. Therefore, they are essential to evaluate pharmacological responses and the pathogenesis of diseases for the therapeutic intervention of kidney disorders. However, blood urea nitrogen (BUN) and serum creatinine (SCr) are not very accurate and specific markers of kidney function in acute coronary syndrome [11]. For instance, the BUN and SCr are not accurate renal function indexes due to the abnormal BUN/SCr ratio observed in patients with heart failure [12]. The levels of the serum biomarkers mentioned above and urine biomarkers among patients with liver failure were affected by numerous factors, including ingestion of creatinine, excretion of drugs, protein intake, sex, and age [13]. Loss of muscle mass will lead to overestimating the glomerular filtration rate (GFR). Thus, using SCr to assess kidney function accurately is prone to error in steady-state situations [14]. Therefore, this review summarized the potential biomarkers to improve renal function deterioration and detection accuracy in the early stage of kidney damage.
Much fundamental research has made unprecedented progress in detecting novel kidney biomarkers [15,16]. Early diagnostic methods benefit from choosing the most appropriate preclinical drug and the mechanistic understanding of human nephropathy. So far, studies on blood and urine biomarkers in renal biopsy of animals are widely used strategies to understand the mechanisms of kidney-related disease and to develop successful treatments. Nevertheless, considering the ethical treatment of animals, the 3Rs principles of replacement, reduction, and refinement were developed to avoid unethical research more than 50 years ago [17]. Various practical alternative methodologies have been created for assessing the possible harmful substances of chemicals. The 3Rs offer a method for reducing animal usage and suffering in studies while maintaining the standard of scientific work being done logically and step-by-step. Today, alternative methods are important in reducing the number of experimental animals for hazard identification and safety assessments. Advanced alternative strategies, including in vitro and in silico methods, are also used for kidney safety assessment or prediction during drug development [18]. To study the multiple causes of kidney failure, many mammalian model systems have been used to investigate the mechanisms of renal injury progression and identify potential targets for early clinical trials of lead drug discovery [19,20,21].
However, recent studies have indicated that animal models do not precisely simulate human diseases or biological processes [22,23]. In addition, alternative methods have become essential for animal experimental replacement to provide more ethical and humane research approaches [24,25]. Advanced alternative methods, such as in vitro cell culture, human organoids, and in silico methods, provide unique opportunities for the safety assessment of drug candidates and for studying human disease to overcome these limitations [26,27,28]. For example, integrated testing strategies using computer models and some instruments (e.g., mass spectrometry, functional and pharmacological magnetic resonance imaging, and flow cytometry) have facilitated measurable progress to produce valuable data [29]. The advantages of the above technologies lead to a reduction in the number of animals and help to achieve the goals of the 3Rs in research. Hence, these methods may provide a powerful strategy for developing appropriate drugs and identifying new therapeutic approaches. This review presents a series of modern clinical and nonclinical research strategies and summarizes the valuable tools of current assessments, including models of kidney disease and alternative methods.

2. Protein Biomarkers of Kidney Safety to Predict and Diagnose Kidney Disease in Preclinical and Clinical Studies

The term biomarker is short for “biological marker”, also called molecular marker, and is a signature molecule found in body fluids, blood, and tissues in normal conditions or disease [30]. Generally, biomarkers indicate the physiological status and may be used as analytic or measurable disease features to monitor the body’s responses [31,32]. Biomarkers also play an important role in developing medical devices and lead compounds during drug development [33], providing valuable data after measuring the responses of pharmacodynamics, pathogenic processes, and biological processes after treatment with medical interventions [34]. However, there is considerable misunderstanding about the biomarkers’ definitions and ability to serve as predictive, diagnostic, and prognostic markers. Biomarkers can be categorized into seven kinds of detection: predictive [35], susceptibility [36], diagnostic [37], prognostic [38], monitoring [39], pharmacodynamic [40], and safety [41]. Moreover, these approaches have the potential to provide a powerful tool for the development of new therapeutic strategies and for monitoring the benefits of administered drugs. Predictive biomarkers can often measure observational data in response to therapeutic interventions of interest before treatment and provide information in clinical practice for preventing kidney failure [42]. The important protein biomarkers of kidney safety for assessing kidney disease status are discussed in the following subsections.

2.1. Protein Biomarkers for the Prediction, Diagnosis, and Prognosis of Kidney Injury

The traditionally used endogenous marker can be predictive, diagnostic, and prognostic in the different stages of kidney failure (Figure 1). The predictive biomarkers approved by the FDA and EMEA for detecting kidney damage [43] include the urine biomarkers of kidney injury molecule-1 (KIM-1) [44], urinary neutrophil gelatinase-associated lipocalin (NGAL) [45], interleukin-18 (IL-18) [46], and liver fatty acid-binding protein (L-FABP) [47]. Prognostic biomarkers can be a clinical or biological characteristic that provides information from patients with high risk for associated outcomes irrespective of therapy. The prognostic biomarkers of kidney injury include urine biomarkers (KIM-1, cystatin C, netrin-1, and NGAL) and blood biomarkers (creatinine, urea, and NGAL). Prognostic biomarkers can be used to predict the course of disease from observational data and help identify the outcomes of patients with medical conditions or interventions. The prognostic biomarkers associated with kidney disease included urea and creatinine in blood and KIM-1, NGAL, and cystatin C in urine. Urine and serum contain promising biomarkers that can aid in the early detection of kidney injury and identify the mechanism of injury. Thus, they are valuable tools for diagnosis at an early stage to minimize the severity of injury.

2.2. Biomarkers of Inflammation

The inflammatory response and its activation pathways in kidney cells can produce early responses to kidney injury, and various molecules, such as growth factors, chemokines, adhesion molecules, proinflammatory cytokines, and molecular signatures, can be triggered and involved in the inflammatory process. Regarding the biomarkers of kidney inflammation, several previous studies illustrated that the adhesion molecules intercellular adhesion molecule-1 (ICAM-1) [48] and vascular cell adhesion molecule-1 (VCAM-1) [49] and the inflammatory cytokines interleukins (1, 6, 8, 17, 18, and 19) [50,51,52,53], tumor necrosis factor receptors (TNFR1 and TNFR2) [54], nuclear factor kappa B (NF-κB) [55], activator protein 1 (AP-1) [56], C-reactive protein (CRP) [57], and monocyte chemoattractant protein-1 (MCP-1) [58] are the most commonly used mediators to detect inflammation in clinical or nonclinical research.
TNF receptors belong to a protein superfamily of cytokine receptors, which contain glycoproteins with a single-pass transmembrane domain to transmit signals for downstream signaling. Inflammatory responses are mediated by the binding of TNF-α to TNF receptors and contribute to apoptosis through the activation of NF-κB and AP-1. Recently, TNFR1 and TNFR2, biomarkers of low-grade inflammation, are important indicators for kidney disease diagnosis [59]. Additionally, the inflammatory cytokine TNF-α is the most extensively studied molecule. For instance, patients with renal failure generally have higher expression levels of TNF-α than healthy patients [60]. During the progression of the inflammatory response by kidney injury, patients with albuminuria have higher levels of TNF-α than patients without albuminuria. Another previous study demonstrated that the TNF receptor TNFR2 protein binding to TNF-α was positively associated with albuminuria and tissue injury in the progression of diabetic nephropathy [61]. Therefore, TNF-α can serve as an important indicator in the progression of kidney injury and has been regarded as an attractive target of inflammatory cytokines in developing novel therapeutic agents for kidney failure. Regarding CKD, early studies have also illustrated that increased levels of circulating TNFRs are strongly related to the progression of kidney damage caused by diabetes, stage 3 CKD, and end-stage kidney disease [62].

2.3. Biomarkers of Nephrotoxicity

Traditionally, safety biomarkers can provide crucial technical assistance in risk assessment and can be broadly used to monitor kidney safety after exposure to a medical product. Hence, the use of safety biomarkers can inform the extent of toxicity and assist in the early detection of kidney injury to predict the clinical nephrotoxicity risk during the progression of drug treatment. In early drug development, the primary challenge is accurately assessing toxicity risk to differentiate compounds in clinical trials [63]. Traditional nephrotoxicity biomarkers, including BUN and serum creatinine, have poor timing accuracy and low sensitivity for diagnosis. Therefore, precise or sensitive safety biomarkers are needed for a more specific diagnosis of nephrotoxicity for risk minimization. The outcome may help identify kidney failure’s severity after intervention in nephrotoxicity signaling. The promising prognostic biomarkers in different kidney units for monitoring nephrotoxic drugs are described in Table 1. For instance, the proinflammatory cytokines or chemokines released by leukocytes, including IL-6, IL-18, IL-10, MCP-1, IFNγ, TGF-β, and CXCL1, were the target of preclinical studies or drug development in proximal tubular epithelial cells for the early diagnosis of AKI [64]. Some studies have demonstrated that IL-18 is a crucial mediator of acute injury in the renal parenchyma and tubular cells. These biomarkers mentioned above are more specific and sensitive for detecting AKI at an earlier stage of kidney injury, and a rapid diagnosis can be applied to identify patients with a high risk of AKI. Approximately one hundred traditional biomarkers were discovered from previous reports to evaluate safety risk. No unrivaled biomarker is available in routine clinical practice [65].

3. Currently Used Experimental Models to Assess the Drug Mechanism in Kidney Therapy

Experimental animal models have been widely used to investigate nephropathy events, study the underlying mechanisms of renal disease, discover specific biomarkers, and identify potential targets for kidney therapy [65,66]. AKI can be regarded as an irreversible renal function that increases the risk of CKD’s development. In this section, we focus on mouse and rat models that mimic human AKI and CKD to study the efficiency and safety of interventions and treatments of interest. Current models of AKI and CKD can be induced by endogenous toxins (sepsis), ureteral obstruction, ischemia–reperfusion (IR), treatment with chemicals (cisplatin, folic acid, etc.), unilateral nephrectomy, and hypertensive nephropathy. The above critical information on the current various animal models is summarized in Table 2. Different murine models of mice and rats are relatively inexpensive and easily maintained. However, the recently available models, including their model techniques, the types of models, and modeling time, are not mentioned clearly. Here, we will discuss the platform of AKI and CKD models, including their engineered method, surgical operations, model time courses, disease induction of toxins, and the dose ranges for treatment.

3.1. Sepsis-Induced Models

Generally, sepsis-associated AKI can be considered severely inflammatory and has become a frequently studied model in rats and mice [79]. The major models used for AKI induction have two types of strategies: (1) injection of bacteria or endogenous toxins to establish a lipopolysaccharide (LPS) mouse model that triggers stronger immunity [80], and (2) two needle punctures into the abdominal cavity to create the symptoms of bacterial peritonitis as a cecal ligation and puncture (CLP) model [81]. The commonly used experimental drug dosage is 10–15 mg/kg LPS [82]. The Toll-like receptor 4 (TLR-4) of immune cells is a specific receptor that can interact with LPS to secrete inflammatory cytokines such as IL-1, IL-6, and TNF-α, leading to sepsis and inflammation at 72–96 h [83]. However, it is difficult to regulate the severity of sepsis in mice, and it is not easy to develop reproducible AKI in CLP models [84].

3.2. Chemical-Induced AKI

Endogenous toxins or poisons are used to induce acute renal failure and play an essential role in developing cardiac surgery-associated AKI [85]. A chemotherapy agent, cisplatin, is widely used in solid tumor therapy [86]. However, high doses of cisplatin can cause nephrotoxicity in humans, leading to AKI or CKD. In particular, the adverse effects of cisplatin are injury to proximal tubules and cell apoptosis or necrosis through oxidative stress, calcium overload, and the inflammatory response. Cell death caused by cisplatin reduces the GFR value [87] and increases vascular resistance [88]. In addition, i.p. injection of aristolochic acid can induce AKI and CKD, which cause proximal tubular cell necrosis and result in kidney fibrosis and oxidative stress. Several studies have employed aristolochic acid-induced kidney failure to explore new therapeutic targets [89].

4. In Vitro and In Silico Alternative Models to Animal Tests for Drug Safety Assessment

Traditionally, millions of mammals, including mice and rats, are widely used to identify hazards and safely assess the tested compounds. However, the 3Rs principle defined by W.M.S. Russell (1925–2006) and R.L. Burch (1926–1996) has become essential for minimizing animal use in evaluating potential toxic chemicals over the past years. Several alternative methods, such as in vitro and in silico models, can replace and reduce the number of living animals for modern toxicologists, offering substantial cost savings and increasing the effectiveness of new drug discovery. The advantage of in vitro and in silico models is that they allow us to test drug efficacy and toxicity without animal experiments. Therefore, in vitro models offer new opportunities to model in vivo conditions. To develop nonanimal model alternative methods to support the criteria of consciousness in animals, including replacing, reducing, and refining, the currently used alternative approaches are summarized in Figure 2. The following section discusses potential techniques for the replacement of animals to explore the effects of and responses to drugs and identify genetic pathways involved in the development of drugs.

4.1. In Vitro Renal Models

Traditional in vitro assays and two-dimensional (2D) cell culture systems are widely used in vitro techniques for exploring the mechanisms of diseases, nonclinical testing, drug discovery, and drug risk assessments. The advantages of 2D cultures are low maintenance cost and simple reproducibility [90], and the cells grow as a monolayer in a flat petri dish via adherent 2D cultures to attach the surface [91]. Therefore, most research utilizes 2D cultures to study lead compounds’ pharmacology, efficacy, and safety in biological systems [92]. Over the past decades, the pharmaceutical industry has also utilized 2D cultures to evaluate the properties of pharmacokinetics, such as absorption, distribution, metabolism, and excretion (ADME), and to perform drug risk assessments of newly discovered chemicals in drug development [93]. The proximal tubule cell is a vital nephron segment and is usually regarded as a research target in the nephrotoxic injury study [94]. Developing proximal tubule cell lines from human cells enables researchers to model common types of nephropathies. For instance, in vitro kidney cell models have potentially mimicked the change from normal kidney tissue to early pathologic CKD conditions [95]. A single cell type in a 3D environment in vitro also enables the use of several recently established tissue engineering (TE) techniques as kidney disease models, such as polycystic kidney disease [96], renal cell carcinoma [97], nephronophthisis [98], drug-induced nephrotoxicity [99], and kidney fibrosis [100]. Therefore, much research has focused chiefly on proximal tubule cells to investigate nephrotoxic compounds for safety assessment [101,102]. However, the proximal tubules reabsorb glucose, electrolytes, and albumin that can transport drugs and secrete xenobiotics into the filtrate to disrupt nephrotoxic studies. In addition, the microvasculature in renal cells is also susceptible to drug-induced injury and sensitive to phosphorylation, which can cause inflammation with consequences on tubule function [103].

4.2. Organoid Models of Kidney Diseases

To date, in vitro 2D systems for studying nephrotoxicity are still poorly predictive of toxicity in animals or humans [104]. The major disadvantages of 2D culture are that it does not represent cell–cell and cell–ECM interactions [105]. Thus, there is a need to find better alternative models to mimic natural cell growth and the reality of diseased tissue, such as 3D culture systems. The 3D models appear to better represent animal tissue outside the living species than 2D cell culture models [106]. Undoubtedly, the ideal environment in disease modeling in drug development is 3D cell culture systems instead of traditional monolayer cell cultures and animal models, and they have been used to understand human biology and disease modeling during the past decade [107]. However, the above experimental models still have challenges in mimicking the physiological environment of organs due to the low capacity to fully recapitulate the organization of tissue under in vivo environments [108]. For instance, the vascularization of organoid culture systems in in vitro models can overcome the limitations of mimicking organoid-vasculature interactions to avoid necrotic core formation [109]. Vascularized kidney organoids have recently been derived from human pluripotent stem cells (hPSCs) to mimic in vivo nephrogenesis [110]. The disease modeling applications using hPSC-derived kidney organoids can be applied to study the progression of MUC1 kidney disease [111], ITF40 Nephronophthisis [112], polycystic kidney disease [113], and podocalyxin deficiency [114]. In addition, the kidney organoids also mimic signal cascades and growth factor stimulation. They consist of segmented nephrons and stromal cells and have critical features of the kidney organ [115]. iPSC-derived kidney organoids have been employed in various research fields, including toxicity studies, cell therapy, disease modeling, and drug development [116].

5. In Silico Models for Predicting Drug Safety and Efficacy

The in silico methods for drug design have numerous advantages for modeling pharmacologic or physiologic processes throughout the pharmaceutical industry. For instance, computer-aided drug design (CADD) has become essential to modern drug discovery in different research environments to accelerate therapeutic drug development (Figure 3). One in silico strategy is based on physical knowledge to perform high-throughput virtual screening (HTVS) from existing chemical libraries with millions of small chemicals, including the ZINC database [117], DrugBank [118], and e-Drug3D [119] database, for the identification of potential hits and repurposing of approved molecules for the target of the disease.

5.1. Structure-Based In Silico Methods

Docking-based virtual screening uses computational simulation to evaluate chemical-biomolecule interactions based on 3D structure information. To further study the binding modes of small molecules or macromolecules at the atomic level, molecular dynamics (MD) simulation techniques provide more information or significant complementarity by calculating the potential energy of a system with given positions in space. For instance, quantum mechanics/molecular mechanics (QM/MM) MD simulations combine the accuracy of ab initio QM calculations and speed simulation approaches to study every atom in a protein molecular system and solution. This approach is favorable in investigating features of protein–ligand, protein–protein, protein–nucleic acid, and protein–peptide complexes. Based on a broad model of the physics driving interatomic interactions, MD simulations forecast how each atom in a protein or other molecular system will move over time. The MD simulations can obtain a wide variety of critical biomolecular processes, such as conformational change, ligand interaction, and protein folding, revealing the positions of all the atoms at femtosecond temporal resolution. Importantly, these simulations can also forecast how biomolecules react to alterations like mutations, phosphorylation, protonation, or the addition or removal of ligands at the atomic level. A wide range of experimental structural biology techniques, such as x-ray crystallography [120], cryo-electron microscopy (cryo-EM) [121], nuclear magnetic resonance (NMR) [122], electron paramagnetic resonance (EPR) [123], and fluorescence resonance energy transfer (FRET) [124] are frequently utilized in conjunction with MD simulations. To study the treatments for kidney failure, MD simulations can be applied to investigate several innovative drugs for treating kidney diseases. For instance, studying the mechanical interaction of a ligand on the dynamics of the genetic risk of apolipoprotein L1 (APOL1) enables the discovery of potential inhibitors for CKD disease [125].

5.2. Ligand-Based In Silico Methods

This strategy uses the target’s 3D structure, which is available to determine the nature of the target-ligand interaction and the ligand’s structural requirements. The statistical methods used for ligand-based drug design, such as quantitative structure-activity relationship (QSAR) and pharmacophore, construct relationship models between biological activity and structural information using mathematical algorithms, including linear or nonlinear methods for model generation. The QSAR and pharmacophore approach can be widely utilized in scientific predictions and prevention assessments, such as toxicology assessment, risk prediction, and regulatory decisions. Thus, the ligand-based model can replace animal tests in predicting hazardous substances and analyzing the potentially toxic effects of experimental materials or chemicals in current years. Due to the lack of an experimental structure, the known ligand molecules that bind to the drug target are investigated to determine which of the ligands’ structural and physico-chemical characteristics correspond to the required pharmacological activity of those ligands [126]. In addition to recognized ligand molecules, ligand-based techniques may use natural products or analogs of substrates that interact with the target molecule to produce the desired pharmacological outcome [127]. To study kidney toxicity, the equations of QSAR modeling allow researchers to identify and understand their inhibitory effects related to critical structural features on the renal cells [128]. As an alternative, structure-based approaches, including molecular docking or in silico chemical modification, are typically used for lead optimization when the drug target has a 3D structure [129].

6. Conclusions

Several validated and prevalidated methods can be used as partial or complete alternatives to animal experiments to study the efficacy and toxicity of lead compounds. However, animal ethics is an important issue during the process of hazard identification and assessment of potential biomarkers during the process of kidney injury. The concept of the 3Rs principles facilitates various alternative methods that require investigators to replace traditional animal tests. Several alternative methods, including cell-based methods and computational models, offer an opportunity to reduce the number of experimental animals needed. Despite the reasonable new insights into kidney disease obtained from existing models, many do not fully reproduce kidney disease. Hence, improving kidney disease models is still an important issue. This review has provided a brief overview of the currently used animal models and alternative assessment methods that possibly parallel human kidney disease to offer valuable insights into the pathogenesis of this disease.

Author Contributions

Conceptualization, H.-J.H., Y.-C.L., C.-M.Z. and H.-W.C.; writing—original draft preparation, H.-J.H., C.-L.C., T.T.S., W.-C.L., H.-C.Y., Y.-C.L., C.-M.Z. and H.-W.C.; writing—review and editing, H.-J.H., C.-L.C., T.T.S., W.-C.L., H.-C.Y., Y.-C.L., C.-M.Z. and H.-W.C.; supervision, C.-M.Z. and H.-W.C. All authors have read and agreed to the published version of the manuscript.

Funding

The Ministry of Science and Technology of Taiwan provided funding for this work (MOST 109-2314-B-038-078-MY3, MOST 110-2314-B-038-075-MY3, MOST 111-2314-B-038-154, NSTC 112-2314-B-038-087, and NSTC 112-2221-E-038-016).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zabka, T.S.; Burkhardt, J.; Reagan, W.J.; Gautier, J.-C.; Glaab, W.E.; Guffroy, M.; Harding, J.; Brees, D.; McDuffie, E.; Ramaiah, L.; et al. The use of emerging safety biomarkers in nonclinical and clinical safety assessment—The current and future state: An IQ DruSafe industry survey. Regul. Toxicol. Pharmacol. 2021, 120, 104857. [Google Scholar] [CrossRef] [PubMed]
  2. McDermott, J.E.; Wang, J.; Mitchell, H.; Webb-Robertson, B.J.; Hafen, R.; Ramey, J.; Rodland, K.D. Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data. Expert Opin. Med. Diagn. 2013, 7, 37–51. [Google Scholar] [CrossRef] [PubMed]
  3. Conway, S.R.; Wong, H.R. Biomarker Panels in Critical Care. Crit. Care Clin. 2020, 36, 89–104. [Google Scholar] [CrossRef] [PubMed]
  4. Friedman, L.S.; Ostermeyer, E.A.; Lynch, E.D.; Szabo, C.I.; Anderson, L.A.; Dowd, P.; Lee, M.K.; Rowell, S.E.; Boyd, J.; King, M.C. The search for BRCA1. Cancer Res. 1994, 54, 6374–6382. [Google Scholar]
  5. Provenzano, M.; Rotundo, S.; Chiodini, P.; Gagliardi, I.; Michael, A.; Angotti, E.; Borrelli, S.; Serra, R.; Foti, D.; De Sarro, G.; et al. Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease. Int. J. Mol. Sci. 2020, 21, 5846. [Google Scholar] [CrossRef]
  6. Wang, J.; Yin, Y.; Lu, Q.; Zhao, Y.-r.; Hu, Y.-j.; Hu, Y.-Z.; Wang, Z.-Y. Identification of Important Modules and Hub Gene in Chronic Kidney Disease Based on WGCNA. J. Immunol. Res. 2022, 2022, 4615292. [Google Scholar] [CrossRef]
  7. Sauriasari, R.; Safitri, D.D.; Azmi, N.U. Current updates on protein as biomarkers for diabetic kidney disease: A systematic review. Ther. Adv. Endocrinol. Metab. 2021, 12, 20420188211049612. [Google Scholar] [CrossRef]
  8. Condrat, C.E.; Thompson, D.C.; Barbu, M.G.; Bugnar, O.L.; Boboc, A.; Cretoiu, D.; Suciu, N.; Cretoiu, S.M.; Voinea, S.C. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells 2020, 9, 276. [Google Scholar] [CrossRef]
  9. Ferro, C.J.; Mark, P.B.; Kanbay, M.; Sarafidis, P.; Heine, G.H.; Rossignol, P.; Massy, Z.A.; Mallamaci, F.; Valdivielso, J.M.; Malyszko, J.; et al. Lipid management in patients with chronic kidney disease. Nat. Rev. Nephrol. 2018, 14, 727–749. [Google Scholar] [CrossRef]
  10. Peng, H.; Liu, X.; Aoieong, C.; Tou, T.; Tsai, T.; Ngai, K.; Cheang, H.I.; Liu, Z.; Liu, P.; Zhu, H. Identification of Metabolite Markers Associated with Kidney Function. J. Immunol. Res. 2022, 2022, 6190333. [Google Scholar] [CrossRef]
  11. Adam, A.M.; Nasir, S.A.R.; Merchant, A.Z.; Rizvi, A.H.; Rehan, A.; Shaikh, A.T.; Abbas, A.H.; Godil, A.; Khetpal, A.; Mallick, M.S.A.; et al. Efficacy of serum blood urea nitrogen, creatinine and electrolytes in the diagnosis and mortality risk assessment of patients with acute coronary syndrome. Indian Heart J. 2018, 70, 353–359. [Google Scholar] [CrossRef] [PubMed]
  12. Duan, S.; Li, Y.; Yang, P. Predictive value of blood urea nitrogen in heart failure: A systematic review and meta-analysis. Front. Cardiovasc. Med. 2023, 10, 1189884. [Google Scholar] [CrossRef] [PubMed]
  13. Lewandowska, L.; Małyszko, J.; Matuszkiewicz-Rowińska, J. Urinary and serum biomarkers for prediction of acute kidney injury in patients undergoing liver transplantation. Ann. Transplant. 2019, 24, 291. [Google Scholar] [CrossRef] [PubMed]
  14. Groothof, D.; Post, A.; Polinder-Bos, H.A.; Erler, N.S.; Flores-Guerrero, J.L.; Kootstra-Ros, J.E.; Pol, R.A.; de Borst, M.H.; Gansevoort, R.T.; Gans, R.O.B.; et al. Muscle mass and estimates of renal function: A longitudinal cohort study. J. Cachexia Sarcopenia Muscle 2022, 13, 2031–2043. [Google Scholar] [CrossRef] [PubMed]
  15. Liu, H.; Feng, J.; Tang, L. Early renal structural changes and potential biomarkers in diabetic nephropathy. Front. Physiol. 2022, 13, 1020443. [Google Scholar] [CrossRef]
  16. Mizdrak, M.; Kumrić, M.; Kurir, T.T.; Božić, J. Emerging Biomarkers for Early Detection of Chronic Kidney Disease. J. Pers. Med. 2022, 12, 548. [Google Scholar] [CrossRef]
  17. Calvillo, L. Editorial: 3Rs approach (replace, reduce and refine animal models) to improve preclinical research. Front. Physiol. 2022, 13, 1040575. [Google Scholar] [CrossRef]
  18. Bassan, A.; Alves, V.M.; Amberg, A.; Anger, L.T.; Beilke, L.; Bender, A.; Bernal, A.; Cronin, M.T.D.; Hsieh, J.-H.; Johnson, C.; et al. In silico approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities. Comput. Toxicol. 2021, 20, 100188. [Google Scholar] [CrossRef]
  19. Bufi, R.; Korstanje, R. The impact of genetic background on mouse models of kidney disease. Kidney Int. 2022, 102, 38–44. [Google Scholar] [CrossRef]
  20. Nangaku, M.; Kitching, A.R.; Boor, P.; Fornoni, A.; Floege, J.; Coates, P.T.; Himmelfarb, J.; Lennon, R.; Anders, H.-J.; Humphreys, B.D.; et al. International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology. Kidney Int. 2023, 104, 36–45. [Google Scholar] [CrossRef]
  21. Bartochowski, P.; Gayrard, N.; Bornes, S.; Druart, C.; Argilés, A.; Cordaillat-Simmons, M.; Duranton, F. Gut–Kidney Axis Investigations in Animal Models of Chronic Kidney Disease. Toxins 2022, 14, 626. [Google Scholar] [CrossRef]
  22. Mukherjee, P.; Roy, S.; Ghosh, D.; Nandi, S.K. Role of animal models in biomedical research: A review. Lab. Anim. Res. 2022, 38, 18. [Google Scholar] [CrossRef]
  23. Barroca, N.C.B.; Della Santa, G.; Suchecki, D.; García-Cairasco, N.; de Lima Umeoka, E.H. Challenges in the use of animal models and perspectives for a translational view of stress and psychopathologies. Neurosci. Biobehav. Rev. 2022, 140, 104771. [Google Scholar] [CrossRef]
  24. Caloni, F.; De Angelis, I.; Hartung, T. Replacement of animal testing by integrated approaches to testing and assessment (IATA): A call for in vivitrosi. Arch. Toxicol. 2022, 96, 1935–1950. [Google Scholar] [CrossRef] [PubMed]
  25. Zevnik, B.; Jerchow, B.; Buch, T. 3R measures in facilities for the production of genetically modified rodents. Lab. Anim. 2022, 51, 162–177. [Google Scholar] [CrossRef] [PubMed]
  26. Madani, S.; Machaty, Z.; Vajta, G. An Alternative Way to Improve Mammalian Embryo Development In Vitro: Culture of Zona Pellucida-Free Embryos. Cell. Reprogramming 2022, 24, 111–117. [Google Scholar] [CrossRef] [PubMed]
  27. Mayasich, S.A.; Goldsmith, M.R.; Mattingly, K.Z.; LaLone, C.A. Combining In Vitro and In Silico New Approach Methods to Investigate Type 3 Iodothyronine Deiodinase Chemical Inhibition Across Species. Environ. Toxicol. Chem. 2023, 42, 1032–1048. [Google Scholar] [CrossRef]
  28. Thakkar, Y.; Moustakas, H.; Moelijker, N.; Hendriks, G.; Brandsma, I.; Pfuhler, S.; Api, A.M. Utility of ToxTracker in animal alternative testing strategy for fragrance materials. Environ. Mol. Mutagen. 2023, 64, 234–243. [Google Scholar] [CrossRef]
  29. Krishna, G.; Goel, S.; Krishna, K.A. Chapter 7—Alternative animal toxicity testing and biomarkers. In Biomarkers in Toxicology; Gupta, R.C., Ed.; Academic Press: Boston, MA, USA, 2014; pp. 129–147. [Google Scholar]
  30. Strimbu, K.; Tavel, J.A. What are biomarkers? Curr. Opin. HIV AIDS 2010, 5, 463–466. [Google Scholar] [CrossRef]
  31. Goutman, S.A.; Hardiman, O.; Al-Chalabi, A.; Chió, A.; Savelieff, M.G.; Kiernan, M.C.; Feldman, E.L. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022, 21, 480–493. [Google Scholar] [CrossRef]
  32. Faham, S.; Salimi, A.; Ghavami, R. Electrochemical-based remote biomarker monitoring: Toward Internet of Wearable Things in telemedicine. Talanta 2023, 253, 123892. [Google Scholar] [CrossRef] [PubMed]
  33. Bakker, E.; Hendrikse, N.M.; Ehmann, F.; van der Meer, D.S.; Llinares Garcia, J.; Vetter, T.; Starokozhko, V.; Mol, P.G.M. Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures from 2008 to 2020. Clin. Pharmacol. Ther. 2022, 112, 69–80. [Google Scholar] [CrossRef] [PubMed]
  34. Califf, R.M. Biomarker definitions and their applications. Exp. Biol. Med. 2018, 243, 213–221. [Google Scholar] [CrossRef] [PubMed]
  35. Allinovi, M.; Sessa, F.; Villa, G.; Cocci, A.; Innocenti, S.; Zanazzi, M.; Tofani, L.; Paparella, L.; Curi, D.; Cirami, C.L.; et al. Novel Biomarkers for Early Detection of Acute Kidney Injury and Prediction of Long-Term Kidney Function Decline after Partial Nephrectomy. Biomedicines 2023, 11, 1046. [Google Scholar] [CrossRef]
  36. Wang, Q.; Gümüş, Z.H.; Colarossi, C.; Memeo, L.; Wang, X.; Kong, C.Y.; Boffetta, P. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J. Thorac. Oncol. 2023, 18, 31–46. [Google Scholar] [CrossRef] [PubMed]
  37. Saadeh, R.S.; Ramos, P.A.; Algeciras-Schimnich, A.; Flanagan, E.P.; Pittock, S.J.; Willrich, M.A. An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and Beyond. Clin. Chem. 2022, 68, 1134–1150. [Google Scholar] [CrossRef]
  38. Ding, L.; Gosh, A.; Lee, D.J.; Emri, G.; Huss, W.J.; Bogner, P.N.; Paragh, G. Prognostic biomarkers of cutaneous melanoma. Photodermatol. Photoimmunol. Photomed. 2022, 38, 418–434. [Google Scholar] [CrossRef]
  39. Pourani, M.R.; Abdollahimajd, F.; Zargari, O.; Shahidi Dadras, M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J. Dermatol. Treat. 2022, 33, 1967–1974. [Google Scholar] [CrossRef]
  40. Salawu, A.; Hernando-Calvo, A.; Chen, R.Y.; Araujo, D.V.; Oliva, M.; Liu, Z.A.; Siu, L.L. Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials. Eur. J. Cancer 2022, 173, 167–177. [Google Scholar] [CrossRef]
  41. Sauer, J.-M.; Porter, A.C. Qualification of translational safety biomarkers. Exp. Biol. Med. 2021, 246, 2391–2398. [Google Scholar] [CrossRef]
  42. Priyadarshini, G.; Rajappa, M. Predictive markers in chronic kidney disease. Clin. Chim. Acta 2022, 535, 180–186. [Google Scholar] [CrossRef] [PubMed]
  43. Griffin, B.R.; Faubel, S.; Edelstein, C.L. Biomarkers of Drug-Induced Kidney Toxicity. Ther. Drug Monit. 2019, 41, 213–226. [Google Scholar] [CrossRef] [PubMed]
  44. Tanase, D.M.; Gosav, E.M.; Radu, S.; Costea, C.F.; Ciocoiu, M.; Carauleanu, A.; Lacatusu, C.M.; Maranduca, M.A.; Floria, M.; Rezus, C. The Predictive Role of the Biomarker Kidney Molecule-1 (KIM-1) in Acute Kidney Injury (AKI) Cisplatin-Induced Nephrotoxicity. Int. J. Mol. Sci. 2019, 20, 5238. [Google Scholar] [CrossRef] [PubMed]
  45. Srisawat, N.; Kellum, J.A. The Role of Biomarkers in Acute Kidney Injury. Crit. Care Clin. 2020, 36, 125–140. [Google Scholar] [CrossRef] [PubMed]
  46. Chen, Y.-T.; Jenq, C.-C.; Hsu, C.-K.; Yu, Y.-C.; Chang, C.-H.; Fan, P.-C.; Pan, H.-C.; Wu, I.W.; Cherng, W.-J.; Chen, Y.-C. Acute kidney disease and acute kidney injury biomarkers in coronary care unit patients. BMC Nephrol. 2020, 21, 207. [Google Scholar] [CrossRef]
  47. Tajima, S.; Yamamoto, N.; Masuda, S. Clinical prospects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy. Biochem. Pharmacol. 2019, 170, 113664. [Google Scholar] [CrossRef]
  48. El Alam, S.; Pena, E.; Aguilera, D.; Siques, P.; Brito, J. Inflammation in Pulmonary Hypertension and Edema Induced by Hypobaric Hypoxia Exposure. Int. J. Mol. Sci. 2022, 23, 12656. [Google Scholar] [CrossRef]
  49. Singh, V.; Kaur, R.; Kumari, P.; Pasricha, C.; Singh, R. ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders. Clin. Chim. Acta 2023, 548, 117487. [Google Scholar] [CrossRef]
  50. Mills, K.H.G. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 2023, 23, 38–54. [Google Scholar] [CrossRef]
  51. Aliyu, M.; Zohora, F.T.; Anka, A.U.; Ali, K.; Maleknia, S.; Saffarioun, M.; Azizi, G. Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach. Int. Immunopharmacol. 2022, 111, 109130. [Google Scholar] [CrossRef]
  52. Wang, Y.; Zhang, Y.; Shou, S.; Jin, H. The role of IL-17 in acute kidney injury. Int. Immunopharmacol. 2023, 119, 110307. [Google Scholar] [CrossRef] [PubMed]
  53. Habanjar, O.; Bingula, R.; Decombat, C.; Diab-Assaf, M.; Caldefie-Chezet, F.; Delort, L. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. Int. J. Mol. Sci. 2023, 24, 4002. [Google Scholar] [CrossRef] [PubMed]
  54. Siegmund, D.; Wajant, H. TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond. Nat. Rev. Rheumatol. 2023, 19, 576–591. [Google Scholar] [CrossRef] [PubMed]
  55. Matsumori, A. Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease. Eur. Cardiol. 2023, 18, e40. [Google Scholar] [CrossRef] [PubMed]
  56. Prasad, S.; Kumar, V.; Singh, C.; Singh, A. Crosstalk between phytochemicals and inflammatory signaling pathways. Inflammopharmacology 2023, 31, 1117–1147. [Google Scholar] [CrossRef]
  57. Baião, V.M.; Cunha, V.A.; Duarte, M.P.; Andrade, F.P.; Ferreira, A.P.; Nóbrega, O.T.; Viana, J.L.; Ribeiro, H.S. Effects of Exercise on Inflammatory Markers in Individuals with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Metabolites 2023, 13, 795. [Google Scholar] [CrossRef]
  58. Singh, S.; Anshita, D.; Ravichandiran, V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 2021, 101, 107598. [Google Scholar] [CrossRef]
  59. Lousa, I.; Reis, F.; Santos-Silva, A.; Belo, L. The Signaling Pathway of TNF Receptors: Linking Animal Models of Renal Disease to Human CKD. Int. J. Mol. Sci. 2022, 23, 3284. [Google Scholar] [CrossRef]
  60. Lousa, I.; Reis, F.; Viana, S.; Vieira, P.; Vala, H.; Belo, L.; Santos-Silva, A. TNFR2 as a Potential Biomarker for Early Detection and Progression of CKD. Biomolecules 2023, 13, 534. [Google Scholar] [CrossRef]
  61. Khanijou, V.; Zafari, N.; Coughlan, M.T.; MacIsaac, R.J.; Ekinci, E.I. Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease. Diabetes Metab. Res. Rev. 2022, 38, e3556. [Google Scholar] [CrossRef]
  62. Gohda, T.; Yanagisawa, N.; Murakoshi, M.; Ueda, S.; Nishizaki, Y.; Nojiri, S.; Ohashi, Y.; Ohno, I.; Shibagaki, Y.; Imai, N.; et al. Association between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients with Asymptomatic Hyperuricemia. Front. Med. 2021, 8, 634932. [Google Scholar] [CrossRef] [PubMed]
  63. Troth, S.P.; Vlasakova, K.; Amur, S.; Amin, R.P.; Glaab, W.E. Translational Safety Biomarkers of Kidney Injury. Semin. Nephrol. 2019, 39, 202–214. [Google Scholar] [CrossRef] [PubMed]
  64. Akcay, A.; Nguyen, Q.; Edelstein, C.L. Mediators of Inflammation in Acute Kidney Injury. Mediat. Inflamm. 2009, 2009, 137072. [Google Scholar] [CrossRef] [PubMed]
  65. Jana, S.; Mitra, P.; Roy, S. Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review. Diseases 2023, 11, 8. [Google Scholar] [CrossRef] [PubMed]
  66. Shimosawa, T. How animal models can be utilized to find new biomarkers for cardiovascular diseases. Clin. Sci. 2023, 137, 527–535. [Google Scholar] [CrossRef]
  67. Li, Y.; Ma, J.; Diao, J.; Chen, W.; Wang, Z. Esmolol inhibits cognitive impairment and neuronal inflammation in mice with sepsis-induced brain injury. Transl. Neurosci. 2023, 14, 20220297. [Google Scholar] [CrossRef]
  68. Grande, M.T.; Pérez-Barriocanal, F.; López-Novoa, J.M. Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. J. Inflamm. 2010, 7, 19. [Google Scholar] [CrossRef]
  69. Burek, M.; Burmester, S.; Salvador, E.; Möller-Ehrlich, K.; Schneider, R.; Roewer, N.; Nagai, M.; Förster, C.Y. Kidney Ischemia/Reperfusion Injury Induces Changes in the Drug Transporter Expression at the Blood–Brain Barrier in vivo and in vitro. Front. Physiol. 2020, 11, 569881. [Google Scholar] [CrossRef]
  70. Perše, M.; Večerić-Haler, Ž. Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges. BioMed Res. Int. 2018, 2018, 1462802. [Google Scholar] [CrossRef]
  71. Zaghloul, M.S.; Abdelrahman, R.S. Nilotinib ameliorates folic acid-induced acute kidney injury through modulation of TWEAK and HSP-70 pathways. Toxicology 2019, 427, 152303. [Google Scholar] [CrossRef]
  72. Al Asmari, A.K.; Al Sadoon, K.T.; Obaid, A.A.; Yesunayagam, D.; Tariq, M. Protective effect of quinacrine against glycerol-induced acute kidney injury in rats. BMC Nephrol. 2017, 18, 41. [Google Scholar] [CrossRef] [PubMed]
  73. Udupa, V.; Prakash, V. Gentamicin induced acute renal damage and its evaluation using urinary biomarkers in rats. Toxicol. Rep. 2019, 6, 91–99. [Google Scholar] [CrossRef] [PubMed]
  74. Brodsky, S.V. Anticoagulants and acute kidney injury: Clinical and pathology considerations. Kidney Res. Clin. Pract. 2014, 33, 174–180. [Google Scholar] [CrossRef] [PubMed]
  75. van Koppen, A.; Verhaar, M.C.; Bongartz, L.G.; Joles, J.A. 5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat. J. Vis. Exp. 2013, 77, e50398. [Google Scholar] [CrossRef]
  76. Maranduca, M.A.; Clim, A.; Pinzariu, A.C.; Statescu, C.; Sascau, R.A.; Tanase, D.M.; Serban, D.N.; Branisteanu, D.C.; Branisteanu, D.E.; Huzum, B.; et al. Role of arterial hypertension and angiotensin II in chronic kidney disease (Review). Exp. Ther. Med. 2023, 25, 153. [Google Scholar] [CrossRef]
  77. Deeds, M.C.; Anderson, J.M.; Armstrong, A.S.; Gastineau, D.A.; Hiddinga, H.J.; Jahangir, A.; Eberhardt, N.L.; Kudva, Y.C. Single dose streptozotocin-induced diabetes: Considerations for study design in islet transplantation models. Lab. Anim. 2011, 45, 131–140. [Google Scholar] [CrossRef]
  78. Jefferson, J.A.; Pippin, J.W.; Shankland, S.J. Experimental models of membranous nephropathy. Drug Discov. Today Dis. Models 2010, 7, 27–33. [Google Scholar] [CrossRef]
  79. Kuwabara, S.; Goggins, E.; Okusa, M.D. The Pathophysiology of Sepsis-Associated AKI. Clin. J. Am. Soc. Nephrol. 2022, 17, 1050–1069. [Google Scholar] [CrossRef]
  80. Yu, X.; Yao, H.; Zhang, X.; Liu, L.; Liu, S.; Dong, Y. Comparison of LPS and MS-induced depressive mouse model: Behavior, inflammation and biochemical changes. BMC Psychiatry 2022, 22, 590. [Google Scholar] [CrossRef]
  81. Drechsler, S.; Osuchowski, M. Cecal Ligation and Puncture. In Sepsis: Methods and Protocols; Walker, W.E., Ed.; Springer: New York, NY, USA, 2021; pp. 1–8. [Google Scholar] [CrossRef]
  82. Thomas, R.C.; Bath, M.F.; Stover, C.M.; Lambert, D.G.; Thompson, J.P. Exploring LPS-induced sepsis in rats and mice as a model to study potential protective effects of the nociceptin/orphanin FQ system. Peptides 2014, 61, 56–60. [Google Scholar] [CrossRef]
  83. Kim, Y.K.; Hwang, J.H.; Lee, H.T. Differential susceptibility to lipopolysaccharide affects the activation of toll-like-receptor 4 signaling in THP-1 cells and PMA-differentiated THP-1 cells. Innate Immun. 2022, 28, 122–129. [Google Scholar] [CrossRef] [PubMed]
  84. Schabbauer, G. Polymicrobial sepsis models: CLP versus CASP. Drug Discov. Today Dis. Models 2012, 9, e17–e21. [Google Scholar] [CrossRef]
  85. Al-Githmi, I.S.; Abdulqader, A.A.; Alotaibi, A.; Aldughather, B.A.; Alsulami, O.A.; Wali, S.M.; Alghamdi, M.S.; Althabaiti, T.S.; Melebary, T.B. Acute Kidney Injury After Open Heart Surgery. Cureus 2022, 14, e25899. [Google Scholar] [CrossRef] [PubMed]
  86. Han, L.; Fan, L.; Xingyu, J.; Weijing, Z.; Tong, X.; Qiuzhong, P.; Liming, C.; Jingjing, Z.; Desheng, W.; Yue, L.; et al. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J. Immunother. Cancer 2022, 10, e004029. [Google Scholar] [CrossRef]
  87. Koshkin, V.S.; Barata, P.C.; Rybicki, L.A.; Zahoor, H.; Almassi, N.; Redden, A.M.; Fergany, A.F.; Kaouk, J.; Haber, G.-P.; Stephenson, A.J.; et al. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients with Diminished Renal Function. Clin. Genitourin. Cancer 2018, 16, e879–e892. [Google Scholar] [CrossRef] [PubMed]
  88. Li, Z.; Li, S.; Wen, Y.; Chen, J.; Liu, K.; Jia, J. MiR-495 Inhibits Cisplatin Resistance and Angiogenesis in Esophageal Cancer by Targeting ATP7A. Technol. Cancer Res. Treat. 2021, 20, 15330338211039127. [Google Scholar] [CrossRef]
  89. Zhang, Q.; Luo, P.; Chen, J.; Yang, C.; Xia, F.; Zhang, J.; Tang, H.; Liu, D.; Gu, L.; Shi, Q.; et al. Dissection of Targeting Molecular Mechanisms of Aristolochic Acid-induced Nephrotoxicity via a Combined Deconvolution Strategy of Chemoproteomics and Metabolomics. Int. J. Mol. Sci. 2022, 18, 2003–2017. [Google Scholar] [CrossRef]
  90. Ponce de León-Rodríguez, M.d.C.; Guyot, J.-P.; Laurent-Babot, C. Intestinal in vitro cell culture models and their potential to study the effect of food components on intestinal inflammation. Crit. Rev. Food Sci. Nutr. 2019, 59, 3648–3666. [Google Scholar] [CrossRef]
  91. Kicha, A.A.; Kalinovsky, A.I.; Malyarenko, T.V.; Malyarenko, O.S.; Ermakova, S.P.; Popov, R.S.; Stonik, V.A.; Ivanchina, N.V. Disulfated ophiuroid type steroids from the Far Eastern starfish Pteraster marsippus and their cytotoxic activity on the models of 2D and 3D cultures. Mar. Drugs 2022, 20, 164. [Google Scholar] [CrossRef]
  92. Mittal, R.; Woo, F.W.; Castro, C.S.; Cohen, M.A.; Karanxha, J.; Mittal, J.; Chhibber, T.; Jhaveri, V.M. Organ-on-chip models: Implications in drug discovery and clinical applications. J. Cell. Physiol. 2019, 234, 8352–8380. [Google Scholar] [CrossRef]
  93. Huang, S.-M.; Strong, J.M.; Zhang, L.; Reynolds, K.S.; Nallani, S.; Temple, R.; Abraham, S.; Habet, S.A.; Baweja, R.K.; Burckart, G.J.; et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process. J. Clin. Pharmacol. 2008, 48, 662–670. [Google Scholar] [CrossRef] [PubMed]
  94. Hall, A.M.; Trepiccione, F.; Unwin, R.J. Drug toxicity in the proximal tubule: New models, methods and mechanisms. Pediatr. Nephrol. 2022, 37, 973–982. [Google Scholar] [CrossRef] [PubMed]
  95. Petreski, T.; Varda, L.; Gradišnik, L.; Maver, U.; Bevc, S. Renal Proximal Tubular Epithelial Cells: From Harvesting to Use in Studies. Nephron 2023, 7, 1–5. [Google Scholar] [CrossRef] [PubMed]
  96. Syed Mohamed, S.M.D.; Welsh, G.I.; Roy, I. Renal tissue engineering for regenerative medicine using polymers and hydrogels. Biomater. Sci. 2023, 11, 5706–5726. [Google Scholar] [CrossRef] [PubMed]
  97. Shapiro, D.D.; Virumbrales-Muñoz, M.; Beebe, D.J.; Abel, E.J. Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics. Front. Oncol. 2022, 12, 871252. [Google Scholar] [CrossRef]
  98. Ziegler, W.H.; Lüdiger, S.; Hassan, F.; Georgiadis, M.E.; Swolana, K.; Khera, A.; Mertens, A.; Franke, D.; Wohlgemuth, K.; Dahmer-Heath, M.; et al. Primary URECs: A source to better understand the pathology of renal tubular epithelia in pediatric hereditary cystic kidney diseases. Orphanet J. Rare Dis. 2022, 17, 122. [Google Scholar] [CrossRef]
  99. Yu, P.; Duan, Z.; Liu, S.; Pachon, I.; Ma, J.; Hemstreet, G.P.; Zhang, Y. Drug-Induced Nephrotoxicity Assessment in 3D Cellular Models. Micromachines 2022, 13, 3. [Google Scholar] [CrossRef]
  100. Lake, B.B.; Menon, R.; Winfree, S.; Hu, Q.; Melo Ferreira, R.; Kalhor, K.; Barwinska, D.; Otto, E.A.; Ferkowicz, M.; Diep, D.; et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 2023, 619, 585–594. [Google Scholar] [CrossRef]
  101. Perazella, M.A. Drug-induced acute kidney injury: Diverse mechanisms of tubular injury. Curr. Opin. Crit. Care 2019, 25, 550–557. [Google Scholar] [CrossRef]
  102. Le, T.A.; Hiba, T.; Chaudhari, D.; Preston, A.N.; Palowsky, Z.R.; Ahmadzadeh, S.; Shekoohi, S.; Cornett, E.M.; Kaye, A.D. Aminoglycoside-Related Nephrotoxicity and Ototoxicity in Clinical Practice: A Review of Pathophysiological Mechanism and Treatment Options. Adv. Ther. 2023, 40, 1357–1365. [Google Scholar] [CrossRef]
  103. Bartlett, C.S.; Jeansson, M.; Quaggin, S.E. Vascular Growth Factors and Glomerular Disease. Annu. Rev. Physiol. 2016, 78, 437–461. [Google Scholar] [CrossRef] [PubMed]
  104. Soo, J.Y.C.; Jansen, J.; Masereeuw, R.; Little, M.H. Advances in predictive in vitro models of drug-induced nephrotoxicity. Nat. Rev. Nephrol. 2018, 14, 378–393. [Google Scholar] [CrossRef] [PubMed]
  105. Ryan, S.-L.; Baird, A.-M.; Vaz, G.; Urquhart, A.J.; Senge, h.; Richard, D.J.; O’Byrne, K.J.; Davies, A.M. Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture. Assay Drug Dev. Technol. 2016, 14, 19–28. [Google Scholar] [CrossRef] [PubMed]
  106. Musah-Eroje, A.; Watson, S. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia. J. Neurooncol. 2019, 142, 231–240. [Google Scholar] [CrossRef]
  107. Huang, X.; Huang, Z.; Gao, W.; Gao, W.; He, R.; Li, Y.; Crawford, R.; Zhou, Y.; Xiao, L.; Xiao, Y. Current Advances in 3D Dynamic Cell Culture Systems. Gels 2022, 8, 829. [Google Scholar] [CrossRef]
  108. Suarez-Martinez, E.; Suazo-Sanchez, I.; Celis-Romero, M.; Carnero, A. 3D and organoid culture in research: Physiology, hereditary genetic diseases and cancer. Cell Biosci. 2022, 12, 39. [Google Scholar] [CrossRef]
  109. Bas-Cristóbal Menéndez, A.; Du, Z.; van den Bosch, T.P.P.; Othman, A.; Gaio, N.; Silvestri, C.; Quirós, W.; Lin, H.; Korevaar, S.; Merino, A.; et al. Creating a kidney organoid-vasculature interaction model using a novel organ-on-chip system. Sci. Rep. 2022, 12, 20699. [Google Scholar] [CrossRef]
  110. Safi, W.; Marco, A.; Moya, D.; Prado, P.; Garreta, E.; Montserrat, N. Assessing kidney development and disease using kidney organoids and CRISPR engineering. Front. Cell Dev. Biol. 2022, 10, 948395. [Google Scholar] [CrossRef]
  111. Dvela-Levitt, M.; Kost-Alimova, M.; Emani, M.; Kohnert, E.; Thompson, R.; Sidhom, E.-H.; Rivadeneira, A.; Sahakian, N.; Roignot, J.; Papagregoriou, G.; et al. Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell 2019, 178, 521–535.e523. [Google Scholar] [CrossRef]
  112. Forbes, T.A.; Howden, S.E.; Lawlor, K.; Phipson, B.; Maksimovic, J.; Hale, L.; Wilson, S.; Quinlan, C.; Ho, G.; Holman, K.; et al. Patient-iPSC-Derived Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and Reveal Underlying Pathogenetic Mechanisms. Am. J. Hum. Genet. 2018, 102, 816–831. [Google Scholar] [CrossRef]
  113. Low, J.H.; Li, P.; Chew, E.G.Y.; Zhou, B.; Suzuki, K.; Zhang, T.; Lian, M.M.; Liu, M.; Aizawa, E.; Rodriguez Esteban, C.; et al. Generation of Human PSC-Derived Kidney Organoids with Patterned Nephron Segments and a De Novo Vascular Network. Cell Stem Cell 2019, 25, 373–387.e379. [Google Scholar] [CrossRef] [PubMed]
  114. Kim, Y.K.; Refaeli, I.; Brooks, C.R.; Jing, P.; Gulieva, R.E.; Hughes, M.R.; Cruz, N.M.; Liu, Y.; Churchill, A.J.; Wang, Y.; et al. Gene-Edited Human Kidney Organoids Reveal Mechanisms of Disease in Podocyte Development. Stem Cells 2017, 35, 2366–2378. [Google Scholar] [CrossRef]
  115. Little, M.H.; Combes, A.N. Kidney organoids: Accurate models or fortunate accidents. Genes Dev. 2019, 33, 1319–1345. [Google Scholar] [CrossRef] [PubMed]
  116. Nicholson, M.W.; Ting, C.-Y.; Chan, D.Z.H.; Cheng, Y.-C.; Lee, Y.-C.; Hsu, C.-C.; Huang, C.-Y.; Hsieh, P.C.H. Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy. Cells 2022, 11, 1853. [Google Scholar] [CrossRef] [PubMed]
  117. Sterling, T.; Irwin, J.J. ZINC 15—Ligand Discovery for Everyone. J. Chem. Inf. Model. 2015, 55, 2324–2337. [Google Scholar] [CrossRef] [PubMed]
  118. Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z.; et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018, 46, D1074–D1082. [Google Scholar] [CrossRef]
  119. Douguet, D. Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs. ACS Med. Chem. Lett. 2018, 9, 204–209. [Google Scholar] [CrossRef]
  120. Meisburger, S.P.; Case, D.A.; Ando, N. Robust total X-ray scattering workflow to study correlated motion of proteins in crystals. Nat. Commun. 2023, 14, 1228. [Google Scholar] [CrossRef]
  121. Vant, J.W.; Sarkar, D.; Nguyen, J.; Baker, A.T.; Vermaas, J.V.; Singharoy, A. Exploring cryo-electron microscopy with molecular dynamics. Biochem. Soc. Trans. 2022, 50, 569–581. [Google Scholar] [CrossRef]
  122. Oxenfarth, A.; Kümmerer, F.; Bottaro, S.; Schnieders, R.; Pinter, G.; Jonker, H.R.A.; Fürtig, B.; Richter, C.; Blackledge, M.; Lindorff-Larsen, K.; et al. Integrated NMR/Molecular Dynamics Determination of the Ensemble Conformation of a Thermodynamically Stable CUUG RNA Tetraloop. J. Am. Chem. Soc. 2023, 145, 16557–16572. [Google Scholar] [CrossRef]
  123. Bogetti, X.; Saxena, S.K. Integrating Electron Paramagnetic Resonance Spectroscopy and Computational Modeling to Measure Protein Structure and Dynamics. ChemPlusChem 2023, e202300506. [Google Scholar] [CrossRef] [PubMed]
  124. Hirashima, S.; Park, S.; Sugiyama, H. Evaluation by Experimentation and Simulation of a FRET Pair Comprising Fluorescent Nucleobase Analogs in Nucleosomes. Chem. A Eur. J. 2023, 29, e202203961. [Google Scholar] [CrossRef] [PubMed]
  125. Mayanja, R.; Kintu, C.; Diabate, O.; Soremekun, O.; Oluwagbemi, O.O.; Wele, M.; Kalyesubula, R.; Jjingo, D.; Chikowore, T.; Fatumo, S. Molecular Dynamic Simulation Reveals Structure Differences in APOL1 Variants and Implication in Pathogenesis of Chronic Kidney Disease. Genes 2022, 13, 1460. [Google Scholar] [CrossRef] [PubMed]
  126. Loew, G.H.; Villar, H.O.; Alkorta, I. Strategies for Indirect Computer-Aided Drug Design. Pharm. Res. 1993, 10, 475–486. [Google Scholar] [CrossRef] [PubMed]
  127. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4, 206–220. [Google Scholar] [CrossRef]
  128. Huang, H.-J.; Lee, Y.-H.; Chou, C.-L.; Zheng, C.-M.; Chiu, H.-W. Investigation of potential descriptors of chemical compounds on prevention of nephrotoxicity via QSAR approach. Comput. Struct. Biotechnol. J. 2022, 20, 1876–1884. [Google Scholar] [CrossRef]
  129. Huang, H.-J.; Lee, Y.-H.; Sung, L.-C.; Chen, Y.-J.; Chiu, Y.-J.; Chiu, H.-W.; Zheng, C.-M. Drug repurposing screens to identify potential drugs for chronic kidney disease by targeting prostaglandin E2 receptor. Comput. Struct. Biotechnol. J. 2023, 21, 3490–3502. [Google Scholar] [CrossRef]
Biomolecules 13 01581 g001
Figure 1. Biomarkers of kidney injury: the traditionally used markers in blood and urine are predictive, diagnostic, and prognostic characteristics of the different processes of kidney injury. Serum and urinary biomarkers of kidney disease facilitate earlier detection and prevention to establish effective therapies.
Figure 1. Biomarkers of kidney injury: the traditionally used markers in blood and urine are predictive, diagnostic, and prognostic characteristics of the different processes of kidney injury. Serum and urinary biomarkers of kidney disease facilitate earlier detection and prevention to establish effective therapies.
Biomolecules 13 01581 g001
Biomolecules 13 01581 g002
Figure 2. Schematic representation of identification techniques, protein assays, bioinformatics techniques, and molecular dynamics simulations for drug safety and efficacy assays.
Figure 2. Schematic representation of identification techniques, protein assays, bioinformatics techniques, and molecular dynamics simulations for drug safety and efficacy assays.
Biomolecules 13 01581 g002
Biomolecules 13 01581 g003
Figure 3. Flowchart of various CADD methods used in drug discovery (abbreviations: CADD: computer-aided drug design; QM: quantum mechanical; MM: molecular mechanical; QSAR: quantitative structure-activity relationship).
Figure 3. Flowchart of various CADD methods used in drug discovery (abbreviations: CADD: computer-aided drug design; QM: quantum mechanical; MM: molecular mechanical; QSAR: quantitative structure-activity relationship).
Biomolecules 13 01581 g003
Table 1. List of promising prognostic biomarkers of nephrotoxicity induced by drug with cytotoxicity.
Table 1. List of promising prognostic biomarkers of nephrotoxicity induced by drug with cytotoxicity.
The Functional Unit of the KidneyBiomarkersNephrotoxic Drug
Proximal tubuleInterferons, Interleukins, TNF, CSFs, KIM-1, NGAL, Clusterin, Osteopontin, NAG, Beta-2 microglobulin, AlbuminAminoglycoside, Antibiotics, Amphotericin B, Adefovir, Cyclosporine, Cisplatin, Foscarnet Contrast stain, Cocaine, Heroin, Methadone Methamphetamine Gentamicin, Vancomycin
Distal tubuleSerum cystatin C, NGAL, Clusterin, OsteopontinAminoglycosides, Amphoterin B, Radiocontrast dye, Methotrexate, Vancomycin
GlomerulusInterferons, Interleukins, TNF, CSFs, Type IV collagenACE inhibitor, ARB, NSAIDs, Mitomycin-C, Antiplatelet, Cyclosporin, Quinone
ARB: angiotensin II receptor blockers, NSAIDs: nonsteroidal anti-inflammatory drugs, TNF: tumor necrosis factor, CSFs: colony-stimulating factors, NAG: N-Acetyl-Beta-D-Glucosaminidase, NGAL: Neutrophil Gelatinase-Associated Lipocalin, KIM-1: Kidney Injury Molecule-1, ACE: angiotensin-converting enzyme.
Table 2. Summary of major used experimental AKI and CKD models via traditional animal modeling approaches.
Table 2. Summary of major used experimental AKI and CKD models via traditional animal modeling approaches.
PathologyExperimental ModelsExperimental StrategyReferences
Sepsis-induced AKISepsisSepsis induced by intraperitoneal injection of 10 mg/kg LPS[67]
Obstructive AKIUnilateral ureteric obstruction1–2 weeks of induction for renal fibrosis[68]
Ischemia-reperfusion injuryBilateral renal ischemia for 30 min and then treatment with reperfusion for 24 h[69]
Chemical induced AKICisplatin20 mg/kg of cisplatin within 72 h[70]
Folic acidA single dose of 250 mg/kg Folic acid injection for AKI induction[71]
Glycerol24 h of water deprivation and a single injection of 3–30 mg/kg 25% glycerol[72]
GentamicinDose range 30–200 mg/kg for 4–8 days[73]
Warfarin5/6 nephrectomy rats for 3 weeks and then treated with warfarin for 8 days[74]
CKD caused by mass reduction5/6 nephrectomy (rats)Renal mass reduction by one-sided nephrectomy after removal of the right kidney 1 week[75]
CKD induced by hypertensionAngiotensin II infusion modelsInduction of fibrosis by the increase in the circulating level of angiotensin II[76]
Diabetic nephropathyStreptozotocin mice/ratsA single dose of 200 mg/kg Streptozotocin is directly toxic to pancreatic beta-cells[77]
Membranous nephropathyHeymann nephritis ratsAnti- fraction 1A (Fx1A) antiserum in Sprague-Dawley rats[78]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Huang, H.-J.; Chou, C.-L.; Sandar, T.T.; Liu, W.-C.; Yang, H.-C.; Lin, Y.-C.; Zheng, C.-M.; Chiu, H.-W. Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety. Biomolecules 2023, 13, 1581. https://doi.org/10.3390/biom13111581

AMA Style

Huang H-J, Chou C-L, Sandar TT, Liu W-C, Yang H-C, Lin Y-C, Zheng C-M, Chiu H-W. Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety. Biomolecules. 2023; 13(11):1581. https://doi.org/10.3390/biom13111581

Chicago/Turabian Style

Huang, Hung-Jin, Chu-Lin Chou, Tin Tin Sandar, Wen-Chih Liu, Hsiu-Chien Yang, Yen-Chung Lin, Cai-Mei Zheng, and Hui-Wen Chiu. 2023. "Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety" Biomolecules 13, no. 11: 1581. https://doi.org/10.3390/biom13111581

APA Style

Huang, H. -J., Chou, C. -L., Sandar, T. T., Liu, W. -C., Yang, H. -C., Lin, Y. -C., Zheng, C. -M., & Chiu, H. -W. (2023). Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety. Biomolecules, 13(11), 1581. https://doi.org/10.3390/biom13111581

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop